Luminex received FDA Emergency Use Authorization for COVID-19 antibody test
On Jul. 20, 2020, Luminex announced the FDA had issued an Emergency Use Authorization for the company’s xMAPï¾®…
Phase II human trial of ViralClear’s anti-viral for SARS-CoV-2 Coronavirus launched at 4 key trial sites
On Jul. 13, 2020, BioSig Technologies and its subsidiary, ViralClear Pharma announced the enrollment of adult patients for…
UT Southwestern, Texas Health launched collaborative study to better understand COVID prevalence in DFW
On Jul. 10, 2020, researchers at UT Southwestern Medical Center and Texas Health Resources announced that they will…
Texas A&M, MD Anderson Scientists tested inhaled therapeutic to protect against COVID-19
On Jul. 8, 2020, scientists from Texas A&M University, biopharmaceutical company Pulmotect and MD Anderson Cancer Center announced…
Luminex submitted Emergency Use Authorization request to FDA for COVID-19 antibody test
On Jun. 29, 2020, Luminex announced that the company had submitted an Emergency Use Authorization request to the…
Texas A&M researchers testing COVID-19 vaccine candidates for iBio
On Jun. 24, 2020, a team of scientists at Texas A&M University announced it is working with iBio…
Taconic Biosciences announced distribution of critical COVID-19 mouse model
On Jun. 22, 2020, Taconic Biosciences announced an exclusive agreement with the University of Texas Medical Branch at…
ViralClear opened enrollment with first patient dosing in phase II human trial of anti-viral MMPD oral solution for treatment of COVID-19
On Jun. 17, 2020, BioSig Technologies, and its subsidiary, ViralClear, announced that it had commenced patient enrollment with…
ViralClear added St David’s HealthCare to phase II trial for broad-spectrum oral anti-viral COVID-19 candidate
On Jun. 5, 2020, BioSig Technologies and its subsidiary, ViralClear Pharma, announced it had expanded its patient enrollment…
Tonix Pharma announced FUJIFILM Diosynth Biotechnologies to be nanufacturing partner for COVID-19 vaccine candidate TNX-1800
On Jun. 1, 2020, Tonix Pharmaceuticals announced an agreement whereby FUJIFILM Diosynth Biotechnologies will provide contract manufacturing and…
INOVIO COVID-19 DNA vaccine INO-4800 demonstrated robust neutralizing antibody and T cell immune responses in preclinical models
On May 20, 2020, INOVIO announced the publication of the preclinical study data for IN0-4800, its COVID-19 DNA…
Llama antibody engineered to block Coronavirus
On May 19, 2020, the NIH rported that researchers from the University of Texas, in collaboration with a…
ViralClear published F1000 research in vitro data demonstrating synergy between merimepodib and remdesivir against SARS-CoV-2
On May 14, 2020, BioSig Technologies announced that an article titled, “The IMPDH inhibitor merimepodib provided in combination…
Rice University COVID-19 research fund backed six new initiatives
On May 8, 2020, the Rice University COVID-19 Research Fund Oversight and Review Committee announced it had funded…
XBiotech identified ‘super bloods’ for development of True Human COVID-19 therapy
On May 1, 2020, XBiotech announced that human immune donors had been identified that can support the Company’s…
ViralClear submitted in vitro data on Merimepodib and Remdesivir synergistic activity against COVID-19 novel Coronavirus to peer-reviewed journal
On Apr. 30, 2020, BioSig Technologies announced that an article titled, “The IMPDH inhibitor merimepodib provided in combination…
Texas A&M researchers lead testing of tuberculosis vaccine to fight COVID-19
On Apr. 29, 2020, a team of Texas A&M University researchers asked hundreds of frontline medical workers to…
ViralClear published comparative in vitro data on merimepodib and remdesivir activity against COVID-19 novel Coronavirus in F1000 research
On Apr. 23, 2020, BioSig Technologies announced that an article titled, ﾓThe IMPDH inhibitor merimepodib has similar antiviral…
Bellicum completed sale of Houston facility to MD Anderson for $15 million
On Apr. 15, 2020, Bellicum Pharma announced closing of the sale of its Houston facility to The University…
Positive data generated by Biosig subsidiary ViralClear on Covid-19 Coronavirus published in bioRxiv
On Apr. 9, 2020, BioSig Technologies announced that an article titled “The IMPDH inhibitor merimepodib suppresses SARS-COV-2 replications”…
Texas A&M Researchers designed 3D-printed diffuser to treat COVID-19 patients
On Apr. 8, 2020, a team of Texas A&M University researchers led by Michael R. Moreno, in collaboration…
Luminex received FDA Emergency Use Authorization for ARIES SARS-CoV-2 assay to detect virus responsible for COVID-19 disease
On Apr. 6, 2020, Luminex announced announced that the FDA has issued an Emergency Use Authorization for its…
VGXI established pilot mRNA manufacturing capabilities
On Apr. 6, 2020, VGX announced successful implementation of new RNA production services through completion of all Phase…
Fred Hutch team launched hunt for coronavirus antibodies
On Apr. 2, 2020, a team of scientists at Fred Hutchinson Cancer Research Center in Seattle began searching…
Sorrento announced research testing agreement with University of Texas for preclinical testing of COVID-19 therapeutic product candidates
On Mar. 31, 2020, Sorrento announced it had entered into a research testing agreement with The University of…
Luminex received BARDA contract to support development of second, rapid SARS-CoV-2 test
On Mar. 31, 2020, Luminex announced it had received $642,450 in funding from the Biomedical Advanced Research and…
COVID-19 | Diagnostics | FDA | Medical Device
Luminex receives FDA Emergency Use Authorization for NxTAG CoV Extended Panel to detect SARS-CoV-2 Virus
On Mar. 27, 2020, Luminex announced the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization…
Amneal Pharmaceuticals donated hydroxychloroquine sulfate to state of Texas
On Mar. 26, 2020, Amneal Pharma announced it had donated 1,000,000 hydroxychloroquine sulfate tablets to the Texas State…
iBio announced advancement of COVID-19 vaccine program
On Mar. 26, 2020, iBio announced that immunization studies for its SARS-CoV-2 Virus-Like Particle program (‘IBIO-200’) were proceeding…
iBio supporting AzarGen Biotechnologies’ development of a Rituximab biosimilar at Bryan, Texas facility
On Mar. 26, 2020, iBio announced that it had entered into a development agreement with AzarGen Biotechnologies. Signed…